Latest Announcements

Global Defence Industries Ltd has published unaudited financial results for the quarter and half year ended September 30, 2026, showing a net profit of ₹571.43 crore and a total income from operations of ₹2,909.94 crore.

Kalyani Forge Ltd. has announced an investor presentation for an analyst/investor conference call on November 06, 2026, detailing its Q2 FY27 performance and future plans. The company reported a 118.8% YoY increase in PBT to ₹9.39 Cr and a 86.7% YoY increase in PAT to ₹6.64 Cr. The EBITDA margin improved to 15.3% from 11.1% in H1 FY26. The company has approved a ₹45 Cr funding plan to strengthen liquidity and fund order ramp-up. The presentation highlights the company's growth formula, product offerings, and financial performance.

Optiemus Infracom Limited has informed the Exchange about Investor Presentation, disclosing revised financial results for Q2 FY27 and strategic growth blueprint. The company aims to double revenue in FY27, with a strong focus on EMS, screen protector, and B2C product portfolio. The presentation highlights six building blocks of growth, including a 70:30 JV with Corning International for cover glass, and a high-growth consumer category in drones. The company expects to reach ₹6,500 cr. in FY28 and ₹8,500 cr. in FY29.

Optiemus Infracom Ltd has announced its revised Investor Presentation for Q2FY27, highlighting its strong performance, growth potential, and strategic expansion plans. The company has achieved 401% YoY revenue growth in Q2 FY27, with mobile manufacturing generating ₹500+ cr. revenue. It has also formed a JV with CMF for end-to-end R&D, design, sales, and marketing, and is planning to launch a cover glass JV with Corning International. The company expects to double its revenue in FY27 and reach ₹6,500 cr. in FY28, with a potential revenue growth of 30-35% in FY29.

Kalyani Forge Limited has informed the Exchange about Investor Presentation for the Analyst / Investor Conference Call to be held on November 06, 2026. The presentation highlights the company's Q2 FY27 performance, with a 118.8% YoY increase in PBT to ₹9.39 Cr, and a 38.8% YoY increase in EBITDA to ₹18.67 Cr at a 15.3% margin.

Granules India Ltd reported Q2 and H1 FY27 earnings, with revenue growing 20% YoY to INR15,600 million, and EBITDA and PAT increasing 21% and 39% respectively. The company's growth strategy has multiple pillars, including controlled substances, complex generics, geographical expansion, and peptide CDMO.

Indian Hume Pipe Company Ltd published its unaudited financial results for the 2nd quarter and 1st half year ended September 30, 2026. The company reported a net profit of INR 2274.88 lakhs and an earnings per share of INR 4.32 for the quarter, and INR 4631.83 lakhs and INR 8.79 for the half year.

Granules India Limited has informed the Exchange about the Transcript of the Earnings Conference call for Q2 and the half-year of FY27. The company's revenue grew 20% year-on-year to INR15,600 million, crossing INR15,000 million in quarterly revenue for the first time in its history. EBITDA grew 21%, while PAT increased 39% to INR1,818 million. The company has also uploaded its detailed quarterly presentation and will submit a comprehensive response within 15 business days detailing its corrective and preventive actions following a cGMP inspection by the U.S. FDA.

Fujiyama Power Systems Limited has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs. 13,068 Mn, up 130.1% YoY, and EBITDA at Rs. 2,229 Mn, up 116.4% YoY.

Arvind SmartSpaces Ltd announces record Q2 performance with 110% surge in bookings, driven by successful launches and strong sustenance sales. The company revises its FY27 bookings growth guidance upwards, expecting 70 to 75% year-on-year growth.

Arvind SmartSpaces Limited has announced its revised press release for unaudited financial results for Q2 & H1 FY27, with a 110% surge in bookings and 77% increase in collections.

Fredun Pharmaceuticals Ltd reported a 94% YoY growth in net profit, 92% YoY growth in EBITDA, and 87% YoY growth in revenue for H1 FY27. The company's diversified portfolio spans generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key business highlights include the acquisition of Furlicks, a 26% stake in Goodman Vetcare, and the launch of PAWTALKS as a pet healthcare knowledge platform.

Britannia Industries Ltd has announced its Q2 FY26-27 results, with revenue from operations at Rs 5,542 crores, a 16.6% increase from the previous quarter, and profit after tax at 13.0% of revenue, a 10.2% increase from the previous quarter. The company has also reported a 12-month growth of 13.1% in revenue from operations and a 12.5% increase in profit after tax.

Sai Life Sciences Ltd has released its Q2 FY 2026-27 financial results, showing a 23% year-on-year growth in revenue and a 28% EBITDA margin. The company has also reported a strong business momentum and progress across its key strategic priorities.

Sai Life Sciences Limited has informed the Exchange about Investor Presentation, detailing its Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026. The company reports a healthy performance, with revenue growing by 23% year-on-year, and EBITDA margins standing at 28%. The presentation highlights the company's growing traction with global pharmaceutical companies, increasing adoption of its integrated outsourcing model, and continued progress in building capacity and capabilities.

Sai Life Sciences Ltd reported strong Q2 FY27 revenue growth of 23% YoY, sustaining EBITDA margin. Revenue from Operations was ₹1,213 Cr for H1FY27 compared to ₹1,034 Cr in H1FY26, an increase of 17%. EBITDA stood at ₹335 Cr for H1FY27 compared to ₹281 Cr in H1FY26, an increase of 19%. PAT stood at ₹172 Cr for H1FY27 compared to ₹144 Cr in H1FY26, an increase of 19%. Incurred Capex of ₹621 Cr in H1FY27.

Sai Life Sciences Limited has announced its financial results for the second quarter and half year ended September 2026, reporting a 23% year-on-year revenue growth and a 20% increase in EBITDA. The company has also announced a healthy performance with EBITDA margins standing at 28%.

Cello World Limited has informed the Exchange about Investor Presentation, with Q2 FY27 revenue at ₹633 crore, a growth of 7.8% YoY and 20.2% QoQ. EBITDA and PAT margins stood at 21.3% and 12.9%, respectively. The company expects business performance to improve over the coming quarters.

Cello World Ltd has released its investor presentation for the second quarter ended September 30, 2026, reporting a 7.8% YoY growth in revenue to ₹633 crore, with EBITDA and PAT margins standing at 21.3% and 12.9%, respectively. The company expects business performance to improve in the coming quarters, driven by enhanced operational efficiencies and market penetration.

Excel Industries Limited has informed the Exchange about Investor Presentation, enclosing the unaudited Financial Results for the quarter and half year ended September 30, 2026. The Investor Presentation will also be available on the company's website.